Theratechnologies
Theratechnologies is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies, particularly for HIV, NASH, and oncology. The company markets Trogarzo® and EGRIFTA SV® in the U.S. and is advancing its research pipeline with novel technologies like SORT1+ Technology™.
Theratechnologies Overview
Theratechnologies is a clinical-stage biopharmaceutical company focusing on developing and commercializing innovative therapies. Founded in 1993, the company is headquartered in Montréal, Québec, Canada, with additional headquarters in Dublin, Ireland, and Jersey City, New Jersey. Theratechnologies employs over 100 people across Canada, the United States, and Europe, and it markets prescription products primarily for people with HIV.
HIV Treatments
Theratechnologies currently commercializes two products for the treatment of HIV: Trogarzo® and EGRIFTA SV®. Both are approved by the U.S. Food and Drug Administration (FDA). The company acquired the commercial rights to Trogarzo® in 2016 and it was approved in 2018. Trogarzo® is also under evaluation for an intramuscular mode of administration in collaboration with TaiMed. EGRIFTA® was discovered by Theratechnologies in 1995 and received FDA approval in 2010. The latest F8 formulation of tesamorelin is bioequivalent to the original EGRIFTA®, with a smaller administration volume.
Oncology Research and Development
Theratechnologies is leveraging its novel SORT1+ Technology™ to develop a new class of therapy targeting sortilin (SORT1)-positive cancers. TH1902, a peptide-drug conjugate (PDC), is the leading product derived from this technology. In 2021, TH1902 received Fast-Track Designation from the FDA for developing as a single agent for treating sortilin-positive recurrent advanced solid tumors refractory to standard therapy. A Phase 1 clinical trial is currently ongoing, and long-term efficacy, safety, and pharmacokinetic data are planned to be presented at the 2024 ASCO Meeting.
NASH Drug Development
Theratechnologies is expanding its research pipeline to address unmet medical needs in nonalcoholic steatohepatitis (NASH). The company plans to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for NASH in the general population. This initiative is part of Theratechnologies' broader strategy to diversify its therapeutic focus beyond HIV.
Strategic Initiatives and Achievements
Theratechnologies has made significant strides in its field, reflected in several key recognitions. In 2019, the company ranked 21st on the inaugural TSX30 list, with a stock price increase of 161% from 2016 to 2019. Additionally, in 2022, Theratechnologies was named one of Canada’s Top Small and Medium Employers. These accolades underscore the company's growth and impact within the biopharmaceutical sector.